July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Trends in benign and pre-malignant eyelid tumors: A 10-year analysis in an ocular pathology centre
Author Affiliations & Notes
  • Thiago José Delfraro Delfraro Carmo
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory, Montreal, Quebec, Canada
  • Joao Pedro Romero Braga
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory, Montreal, Quebec, Canada
  • Myriam MacDonald
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory, Montreal, Quebec, Canada
  • Julia Burnier
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory, Montreal, Quebec, Canada
  • Elvira Barbosa Abreu
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory, Montreal, Quebec, Canada
  • Miguel N Burnier
    The MUHC-McGill University Ocular Pathology & Translational Research Laboratory, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Thiago José Delfraro Carmo, None; Joao Pedro Braga, None; Myriam MacDonald, None; Julia Burnier, None; Elvira Abreu, None; Miguel Burnier, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3560. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thiago José Delfraro Delfraro Carmo, Joao Pedro Romero Braga, Myriam MacDonald, Julia Burnier, Elvira Barbosa Abreu, Miguel N Burnier; Trends in benign and pre-malignant eyelid tumors: A 10-year analysis in an ocular pathology centre. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3560.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Benign eyelid lesions represent the majority of biopsied cases in ophthalmology practices. The aim of the study is to review the epidemiology and clinical and histopathological features of benign eyelid tumors.

Methods : From 2008 to 2017, a total of 5222 lesions were studied at the MUHC-McGill University Ocular Pathology & Translational Research Laboratory. Among these, 3,004 lesions occurred in the eyelid, consisting of 1494 benign and premalignant lesions, 1102 inflammatory lesions, and 408 malignant lesions. These lesions were further classified clinically and histopathologically and correlated with patient demographics. Of the 1494 benign lesions, we had complete clinical information for 1185 patients and as such, these cases were included in the present analysis.

Results : Of the 1185 cases, the most common lesions were squamous cell papilloma, nevus, seborrheic keratosis and actinic keratosis. The most affected age range was the sixth decade (average, 61.0 years, range, 15-97 years). Nevus and xantelasma occurred in significantly younger patients than average, while actinic keratosis and seborrheic keratosis occurred in older patients. Among these 1185 lesions, 522 lesions occurred in the lower eyelid, 553 lesions in the upper eyelid, and 110 in the cantus. Overall, there was an insignificant difference between the left and right side with 539 lesions occurring on the left side and 536 lesions on the right side. A total of 677 were diagnosed in women, and 508 in men. A female predominance was found for certain eyelid lesion types, such as nevus.

Conclusions : Benign eyelid tumors are the most common biopsied ocular lesions. Squamous cell papilloma followed by nevus were the most common benign tumors of both upper and lower eyelid. Clinicopathological correlation is essential to diagnose actinic keratosis which should be followed for evidence of malignant transformation.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×